Author: Ken Dropiewski

Milestone Pharmaceuticals Announces First Patient Enrolled in NODE-303 Open-label Safety Study of Etripamil in PSVT

MONTREAL and CHARLOTTE, N.C., Oct. 3, 2019 /PRNewswire/ — Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a Phase 3 clinical-stage biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications, today announced that the first patient has been enrolled in the Phase 3 NODE-303 study. NODE-303 is the Company’s open-label, global safety study of etripamil, […]

Quantum Genomics Reports First Half 2019 Financial Results and Provides Corporate Update

Arterial hypertension: preparing for the pivotal Phase III study of firibastat in patients with resistant arterial hypertension Heart failure: the first patients were enrolled in June in QUORUM, a Phase IIb study of firibastat in heart failure PARIS and NEW YORK, Oct. 03, 2019 (GLOBE NEWSWIRE) — Quantum Genomics (Euronext Growth – FR0011648971 – ALQGC, OTCQX […]

Verve Therapeutics Appoints Cardiologist Andrew Bellinger, M.D., Ph.D., as Chief Scientific Officer

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Verve Therapeutics, a next-generation cardiovascular company developing therapies that safely edit the adult human genome to permanently reduce a person’s risk of coronary artery disease, today announced the appointment of physician and scientist Andrew Bellinger, M.D., Ph.D., as the company’s chief scientific officer. Dr. Bellinger joins Verve from […]

University Hospitals Completes First Evolut™ PRO+ Case in the World

UH Harrington Heart & Vascular Institute continues reputation as global leader in TAVR   CLEVELAND — Physicians at University Hospitals Cleveland Medical Center completed the first procedure in the world using Medtronic’s new Evolut™ PRO+ TAVR System. Guilherme Attizzani, MD, Director, Valve and Structural Heart Disease Center, and Cristian Baeza, […]

Third-party evaluation confirms safety profile of Philips Stellarex .035″ low-dose drug-coated balloon

Primary safety analysis of Stellarex drug-coated balloon (DCB) three-year data, comprising the largest published, pooled set of randomized controlled trial (RCT) data for a single paclitaxel-based device, shows no difference in mortality between patients treated with the Philips Stellarex DCB and those treated with percutaneous angioplasty, the current standard of […]

Endotronix Closes Expanded Series D Financing Round of $70 Million for Heart Failure Solution

LISLE, Ill, Oct. 1, 2019 /PRNewswire/ — Endotronix, Inc., a digital health, medtech company dedicated to advancing the treatment of heart failure (HF), today announced the expansion of its Series D financing round, bringing the total for the round to $70 million. The expansion syndicate for the LSP-led round includes new investment from an additional […]

ControlRad™ Secures $15 Million Series B Financing, Expands Board of Directors

Financing Round Led by Questa Capital to Fuel Commercialization of ControlRad Trace Mobile C-arm Radiation Reduction Technology Medical Device Industry Veterans Ryan Drant and Tim Patrick Join Board ATLANTA–(BUSINESS WIRE)–ControlRad, Inc., a privately held medical technology company focused on dramatically reducing unnecessary radiation exposure during fluoroscopically guided procedures (FGP), today […]

Angel Medical Systems Inc. Assembles World-Class Medical Advisory Board

EATONTOWN, N.J., Oct. 1, 2019 /PRNewswire/ — Angel Medical Systems Inc. is pleased to announce the creation of a Medical Advisory Board (MAB) coincident with the commercial release of the AngelMed Guardian® System, the world’s first implantable Acute Coronary Syndrome (ACS) event detector with real time patient notifications. Members of the MAB will […]

Zynex Announces 95% Order Growth

ENGLEWOOD, Colo., Oct. 2, 2019 /PRNewswire/ — Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in manufacturing and selling non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, today announced 95% year over year order growth for the third quarter 2019. Orders in the third quarter of 2019 […]